Most prevalent comorbidities among COVID-19 are hypertension, diabetes, cardiovascular disease, liver disease, lung disease, malignancy, cerebrovascular disease, COPD and asthma

Objectives:
What is the prevalence of underlying disease in died people with COVID-19?  

Study design:
This review article included 32 articles.

Results and conclusions:   
The investigators found the most prevalent comorbidities among COVID-19 were hypertension, diabetes, cardiovascular disease, liver disease, lung disease, malignancy, cerebrovascular disease, COPD and asthma.

Addition of tocilizumab to standard of care reduces mortality in severe COVID-19 patients

Objectives:
Tocilizumab (TCZ) is an anti-interleukin-6 antibody that has been used for the treatment of severe coronavirus disease 2019 (COVID-19). However, concrete evidence of its benefit in reducing mortality in severe COVID-19 is lacking. Therefore, this review article has been conducted.

Does the addition of tocilizumab to the standard of care reduce mortality in severe COVID-19 patients?  

Severe COVID-19 is associated with increased blood glucose levels

Objectives:
Diabetes mellitus is considered a common comorbidity of COVID-19, which has a wide spectrum of clinical manifestations ranging from asymptomatic infection to severe respiratory symptoms and even death. However, the impact of COVID-19 on blood glucose has not been fully understood. Therefore, this review article has been conducted.

Does COVID-19 infection increase blood glucose and HbA1c levels?  

Pneumococcal vaccine + influenza vaccine probably reduce all-cause mortality in dialysis patients

Objectives:
A lower conversion vaccination rate and a more rapid decline in antibody titers over time in dialysis patients raise concerns about the effectiveness of pneumococcal vaccination (PV) in this population, which has not been systematically reviewed. Therefore, this review article has been conducted.